Minakem-flap
Minakem-flap

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): LB-P8

            Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: LB-P8

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Undisclosed

            Deal Size: $21.0 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing February 26, 2021

            Details:

            LISCure is developing the world's first microbiome-based NASH(non-alcoholic steatohepatitis) treatment, LB-P8, as well as the rheumatoid arthritis treatment, LB-P6, for global clinical trials.